AtriCure, Inc. (ATRC) Rating Reiterated by Canaccord Genuity

AtriCure, Inc. (NASDAQ:ATRC)‘s stock had its “buy” rating restated by Canaccord Genuity in a report released on Monday, October 9th. They currently have a $28.00 price objective on the medical device company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 24.67% from the stock’s current price.

ATRC has been the subject of several other research reports. Zacks Investment Research downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and set a $26.00 price objective (up from $25.00) on shares of AtriCure in a research note on Friday, July 28th. Leerink Swann restated an “outperform” rating and set a $26.00 price objective on shares of AtriCure in a research note on Friday, June 16th. BidaskClub cut AtriCure from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $25.00 target price on shares of AtriCure in a research note on Sunday, July 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $25.83.

Shares of AtriCure (NASDAQ ATRC) opened at 22.46 on Monday. The firm’s market cap is $771.14 million. The stock has a 50 day moving average of $21.85 and a 200-day moving average of $21.95. AtriCure has a 52 week low of $14.78 and a 52 week high of $25.18.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. The company had revenue of $45.23 million during the quarter, compared to the consensus estimate of $44.15 million. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The company’s quarterly revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) EPS. Equities research analysts expect that AtriCure will post ($0.95) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “AtriCure, Inc. (ATRC) Rating Reiterated by Canaccord Genuity” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/18/atricure-inc-atrc-stock-rating-reaffirmed-by-canaccord-genuity.html.

In related news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the completion of the sale, the director now owns 29,967 shares of the company’s stock, valued at approximately $671,260.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 10.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRC. Neuberger Berman Group LLC purchased a new stake in AtriCure in the 1st quarter worth about $10,849,000. Loomis Sayles & Co. L P grew its holdings in AtriCure by 73.5% during the 1st quarter. Loomis Sayles & Co. L P now owns 771,365 shares of the medical device company’s stock valued at $14,772,000 after buying an additional 326,712 shares in the last quarter. Wellington Management Group LLP grew its holdings in AtriCure by 5.6% during the 1st quarter. Wellington Management Group LLP now owns 3,313,575 shares of the medical device company’s stock valued at $63,456,000 after buying an additional 176,025 shares in the last quarter. FMR LLC grew its holdings in AtriCure by 2.7% during the 1st quarter. FMR LLC now owns 4,950,000 shares of the medical device company’s stock valued at $94,793,000 after buying an additional 130,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in AtriCure by 5.7% during the 1st quarter. Vanguar

ATRC has been the subject of several other research reports. Zacks Investment Research downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and set a $26.00 price objective (up from $25.00) on shares of AtriCure in a research note on Friday, July 28th. Leerink Swann restated an “outperform” rating and set a $26.00 price objective on shares of AtriCure in a research note on Friday, June 16th. BidaskClub cut AtriCure from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $25.00 target price on shares of AtriCure in a research note on Sunday, July 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $25.83.

Shares of AtriCure (NASDAQ ATRC) opened at 22.46 on Monday. The firm’s market cap is $771.14 million. The stock has a 50 day moving average of $21.85 and a 200-day moving average of $21.95. AtriCure has a 52 week low of $14.78 and a 52 week high of $25.18.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. The company had revenue of $45.23 million during the quarter, compared to the consensus estimate of $44.15 million. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The company’s quarterly revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) EPS. Equities research analysts expect that AtriCure will post ($0.95) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “AtriCure, Inc. (ATRC) Rating Reiterated by Canaccord Genuity” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/18/atricure-inc-atrc-stock-rating-reaffirmed-by-canaccord-genuity.html.

In related news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the completion of the sale, the director now owns 29,967 shares of the company’s stock, valued at approximately $671,260.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 10.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRC. Neuberger Berman Group LLC purchased a new stake in AtriCure in the 1st quarter worth about $10,849,000. Loomis Sayles & Co. L P grew its holdings in AtriCure by 73.5% during the 1st quarter. Loomis Sayles & Co. L P now owns 771,365 shares of the medical device company’s stock valued at $14,772,000 after buying an additional 326,712 shares in the last quarter. Wellington Management Group LLP grew its holdings in AtriCure by 5.6% during the 1st quarter. Wellington Management Group LLP now owns 3,313,575 shares of the medical device company’s stock valued at $63,456,000 after buying an additional 176,025 shares in the last quarter. FMR LLC grew its holdings in AtriCure by 2.7% during the 1st quarter. FMR LLC now owns 4,950,000 shares of the medical device company’s stock valued at $94,793,000 after buying an additional 130,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in AtriCure by 5.7% during the 1st quarter. Vanguard Group Inc. now owns 1,393,971 shares of the medical device company’s stock valued at $26,695,000 after buying an additional 75,266 shares in the last quarter. 82.11% of the stock is owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply